靶向LCK的分子胶降解剂克服T-ALL抑制剂耐药
该研究通过高通量筛选和药物化学优化,开发了招募cereblon(CRBN)的分子胶降解剂(MGD),可诱导LCK降解并在体外对T-ALL产生强细胞毒性。这些MGD作用于LCK的ATP结合位点远端区域,其活性不受导致抑制剂耐药的gatekeeper突变影响,提示其可克服T-ALL中基于抑制剂的治疗耐药。
要点
- LCK靶向MGD通过CRBN依赖方式降解LCK,体外对T-ALL有强细胞毒性。
- MGD作用于LCK的ATP结合位点远端,活性不受gatekeeper突变影响。
- LCK-CRBN界面涉及G-loop的非经典degron,其突变可破坏相互作用。
核心结论
- LCK靶向分子胶降解剂可克服T-ALL中对基于抑制剂的治疗耐药,为靶向激酶依赖提供新策略。
研究设计与样本
- 研究通过高通量筛选和药物化学优化发现靶向LCK的CRBN招募分子胶降解剂,并进行结构-活性关系分析和三元复合物建模。
主要发现
- MGD诱导CRBN依赖性LCK降解,并在体外对T-ALL产生强细胞毒性。
- 结构-活性关系分析和三元复合物建模揭示LCK-CRBN界面涉及G-loop的非经典degron,其突变破坏该相互作用。
- 与抑制剂及基于抑制剂的PROTAC不同,MGD作用于LCK的ATP结合位点远端区域,其活性不受gatekeeper LCK突变影响。
临床怎么用
- LCK靶向MGD可能作为克服T-ALL激酶抑制剂耐药的策略,尤其适用于gatekeeper突变导致的耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug resistance is a major challenge in cancer therapy, especially in hematologic malignancies in which kinase inhibitors have transformed treatment yet are frequently undermined by drug resistance. Although targeted protein degradation (TPD) offers a mechanistically distinct mode of action compared with inhibition-based therapeutic therapies, the potential value of TPD in drug-resistant blood cancer remains unclear. Here, we report the discovery of cereblon (CRBN)-recruiting molecular glue degraders (MGDs) targeting lymphocyte-specific tyrosine kinase (LCK), an oncogenic kinase in T-cell acute lymphoblastic leukemia (T-ALL). By high-throughput screening and medicinal chemistry optimization, we developed a series of MGDs that induced CRBN-dependent degradation of LCK as well as potent cytotoxicity in T-ALL in vitro. Structure-activity relationship analysis and ternary complex modeling revealed a noncanonical degron at the LCK-CRBN interface involving the G-loop, whose mutation disrupts this interaction. Unlike inhibitors and inhibitor-based proteolysis-targeting chimeras, these MGDs engage LCK in regions distal to the ATP-binding site, and thus their activities in T-ALL are not affected by gatekeeper LCK mutations that drive resistance to inhibitor-based therapeutics. Taken together, our data highlight the potential of LCK-targeting MGDs as a strategy to overcome kinase inhibitor resistance in T-ALL, offering a framework for targeting kinase dependencies in drug-refractory hematologic malignancies more broadly.
引用
- Yoshimura S, Actis M, Seffernick JT, et al. LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia. Blood. 2026. PMID: 42247310. doi:10.1182/blood.2025031127
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。